Advanced search
Publication Cover
Libyan Journal of Medicine Volume 14, 2019 - Issue 1
Submit an article Journal homepage
1,446
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Prevalence of Her3 in gastric cancer and its association with molecular prognostic markers: a Saudi cohort based study

Ayesha AhmedDepartment of Pathology, College of Medicine, Imam Abdulrahman Bin Faisal University and King Fahd Hospital of the University, Al-Khobar, Kingdom of Saudi ArabiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2036-7067View further author information
ORCID Icon
Article: 1574532 | Received 10 Jun 2018, Accepted 16 Jan 2019, Published online: 27 Mar 2019

References

  • Sukawa Y, Yamamoto H, Nosho K, et al. HER2 expression and PI3K-Akt pathway alterations in gastric cancer. Digestion. 2014;89(1):1–7.
  • Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005 Jan 1;65(1):226–235.
  • Cao GD, Chen K, Xiong MM, et al. HER3, but not HER4, plays an essential role in the clinicopathology and prognosis of gastric cancer: a meta-analysis. PloS one. 2016 Aug 18;11(8):e0161219.
  • Berger MB, Mendrola JM, Lemmon MA. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett. 2004 Jul 2;569(1–3):332–336.
  • Le Wilks ST. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway. Breast. 2015 Oct;24(5):548–555.
  • Mishra R, Patel H, Alanazi S, et al. HER3 signaling and targeted therapy in cancer. Oncol Rev. 2018 May 16;12(1):355.
  • Wang L, Yuan H, Li Y, et al. The role of HER3 in gastric cancer. Biomed Pharmacother. 2014 Jul;68(6):809–812.
  • Jaiswal BS, Kljavin NM, Stawiski EW, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013 May 13;23(5):603–617.
  • Cancer Incidence Report Saudi Arabia, Kingdom of Saudi Arabia, Council of Health Services. Saudi cancer registry, April 2014. [cited 2018 Jun 4]. Available from: www.scr.org.sa
  • Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
  • Zhang XL, Yang YS, Xu DP, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg. 2009 Oct;33(10):2112–2118.
  • Busuttil RA, Zapparoli GV, Haupt S, et al. Role of p53 in the progression of gastric cancer. Oncotarget. 2014 Dec 15;5(23):12016–12026.
  • Saricanbaz I, Karahacioglu E, Ekinci O, et al. Prognostic significance of expression of CD133 and Ki-67 in gastric cancer. Asian Pac J Cancer Prev. 2014;15(19):8215–8219.
  • Hayashi M, Inokuchi M, Takagi Y, et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res. 2008 Dec 1;14(23):7843–7849.
  • Wu X, Chen Y, Li G, et al. Her3 is associated with poor survival of gastric adenocarcinoma: her3 promotes proliferation,survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway. Med Oncol. 2014 Apr;31(4):903.
  • Tang D, Liu CY, Shen D, et al. Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas. Onco Targets Ther. 2014 Dec 16;8:7–14.
  • He XX, Ding L, Lin Y, et al. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. J Clin Pathol. 2015;68:374–380.
  • Alshomimi S, Alsaleem H. Comparing the treatment of gastric cancer between Korea and Saudi Arabia. Transl Gastroenterol Hepatol. 2017;2:32.
  • Sanidas EE, Filipe MI, Linehan J, et al. Expression of the c-erbB-3 gene product in gastric cancer. Int J Cancer. 1993 Jul 30;54(6):935–940.
  • Kobayashi M, Iwamatsu A, Shinohara-Kanda A, et al. Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene. 2003 Mar 6;22(9):1294–1301.
  • Srini Srinivasan R, Leverton KE, Sheldon H, et al. Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3. Cell Signal. 2001 May;13(5):321–330.
  • Jácome AA, Wohnrath DR, Scapulatempo NC, et al. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. Gastric Cancer. 2014 Jan;17(1):76–86.
  • Ocana A, Vera-Badillo F, Seruga B, et al. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst. 2013 Feb 20;105(4):266–273.
  • Ko GH, Go SI, Lee WS, et al. Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation. Medicine (Baltimore). 2017 Jun;96(25):e7181.
  • Al-Moundhri MS, Nirmala V, Al-Hadabi I, et al. The prognostic significance of p53, p27 kip1, p21, waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol. 2005 Sep 15;91(4):243–252.
  • Yallowitz AR, Li D, Lobko A, et al. Mutant p53 amplifies epidermal growth factor receptor family signaling to promote mammary tumorigenesis. Mol Cancer Res. 2015 Apr;13(4):743–754.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.